Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, March 7, 2012 at 10:40am Eastern Time (7:40am Pacific Time) during the Cowen and Company 32nd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. In January 2011, Cadence commercially launched OFIRMEV® (acetaminophen) injection, an intravenous formulation of acetaminophen, in the U.S.  For more information about Cadence, please visit www.cadencepharm.com.Contacts:

William R. LaRue  

SVP, CFO 

Cadence Pharmaceuticals, Inc.  

858-436-1400
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
2. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
3. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
4. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
7. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
8. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
10. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Neurim Pharmaceuticals ("Neurim") and Exeltis announced today ... for Neurim,s new Rx PedPRM in Spain . ... Neurim,s paediatric prolonged-release ... children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is ... The collaboration with Exeltis will help increase the accessibility of ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits from the expanding ... Frontier Data, the legal cannabis market is projected to create 283,422 ... the United States , as well as the economic ... that drives growth in this sector. Medical cannabis is now legal ...
(Date:3/28/2017)... LONDON , March 28, 2017 The ... at a CAGR of 13.45% from 2016 to 2023 ... Description Cancer is a chronic disease ... emerging in the cancer diagnostics market. This report is ... tumor test. The market growth is propelled due to ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... management software and services, is proud to announce it has joined the National ... association representing the interests of chronically ill, disabled, and dying Americans of all ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the ... launch of a free, public-facing tool for analyzing the costs of various drug ... provide comparative information to patients, providers, insurers and pharmaceutical companies about the estimated ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading ... Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up ... association with efforts by the American College of Surgeons, U.S. Department of Defense, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
(Date:3/28/2017)... ... 28, 2017 , ... Calibration, qualification, and the appropriate level ... maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled ... these requirements are explained. The challenge is to determine how to put ...
Breaking Medicine News(10 mins):